Stock Taper
SCREENER COMPARE ANY 2 STOCKS
IMMX
IMMIX BIOPHARMA, INC.
NASDAQ
$13.94
▼ DOWN 2.59% (-0.37)

KEY STATISTICS

Market Cap$758.36 M
52w High$15.10
52w Low$1.94
Dividend Yield—
Frequency—
P/E-15.32
Volume1.14M
Shares Out.54.40M

COMPANY

LEADERSHIP

Ilya Rachman
CHIEF EXECUTIVE
Ilya Rachman

COMPENSATION 2026

Salary$475,000
Stock Awards$0
Incentive Plan Pay$285,000
All Other Comp.$0
Total$1,352,854

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 16, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
21

PRICE TARGET

Target High$25.00
Target Low$19.00
Target Median$22.00
Target Consensus$22.00

UPCOMING EARNINGS

DateNov 6, 2026
DayFriday
Rev. Est.—
NOV
6
FRI

PRICE

$13.94 ▼ DOWN 2.59% (−$0.37)
$13.80$13.95$14.109:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM13.94

About Immix Biopharma, Inc.

https://www.immixbio.com ↗

Immix Biopharma, a clinical-stage biopharmaceutical company based in Los Angeles, develops tissue-specific therapeutics for oncology and inflammation, with ongoing trials for soft tissue sarcoma, colorectal cancer, ulcerative colitis, and Crohn's ...

INDUSTRY

Biotechnology

A PRODUCT IMMIX BIOPHARMA, INC. IS KNOWN FOR

NXC-201
NXC-201

NXC-201 is Immix Biopharma’s lead CAR-T cell therapy for relapsed/refractory AL Amyloidosis, in clinical trials, FDA Breakthrough Designation, and its most advanced product candidate.

COMPETITORS

COMPETITOR
BMY COMPARE
CRBU COMPARE
GILD COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
66
LISTED HERE
15
RANKED BY POSITION SIZE
XBI
0.27% · 2.2M
VTI
0.00% · 1.8M
IWM
0.02% · 1.1M
LABU
0.18% · 81.6K
GSSC
0.06% · 43.8K
XRS2.DE
0.02% · 37.6K
BBC
1.01% · 37.1K
RSSL
0.02% · 19.4K
AVSC
0.01% · 13.0K
URTY
0.01% · 1.7K
TNXT
0.10% · 1.3K
PWS
0.06% · 977
FSEG
0.03% · 165
RESM
0.02% · 106
SC0K.DE
0.02% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
40.99%
HOLDERS
94
TOP 12 OF 94 · RANKED BY POSITION SIZE
Janus Henderson Group Plc
4.8M sh · $43.7M
Saturn V Capital Management LLC
3.7M sh · $33.65M
Eventide Asset Management, LLC
2.5M sh · $23.22M
Marshall Wace, Llp
2.0M sh · $10.35M
Millennium Management LLC
1.8M sh · $15.94M
Adage Capital Partners Gp, L.L.C.
1.5M sh · $7.84M
Logos Global Management LP
1.2M sh · $11.16M
Vanguard Group Inc
1.1M sh · $5.73M
Bleichroeder LP
1.0M sh · $9.11M
Blue Owl Capital Holdings LP
986.2K sh · $5.16M
Franklin Resources Inc
980.4K sh · $5.13M
Velan Capital Investment Management LP
740.0K sh · $6.74M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
DIRECTOR
Hsu Jason
Purchase · 6.3K shares
2026-05-22
★
DIRECTOR, OFFICER: CFO, PRESIDENT
Morris Gabriel S
Purchase · 500.0K shares
2026-05-22
★
DIRECTOR
BUCHAN JANE
Purchase · 6.3K shares
2026-05-22
★
DIRECTOR
Marquet Magda
Purchase · 12.5K shares
2026-05-22

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 1
BUY 1
OUTPERFORM 1
MARKET OUTPERFORM 1
4 GRADES IN THE LAST 12 MONTHS
Morgan Stanley OVERWEIGHT HC Wainwright & Co. BUY Mizuho OUTPERFORM Citizens MARKET OUTPERFORM

SECTORS PEERS

PEERPRICE
ZNTL$3.80COMPARE
WHWK$4.62COMPARE
MGNX$4.13COMPARE
ORMP$5.03COMPARE
SRZN$22.42COMPARE
COYA$4.59COMPARE
ONCY$0.86COMPARE
PLRX$1.11COMPARE